วัคซีนโควิด-19
แหล่งข้อมูลอื่น

↑  
"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults". ClinicalTrials.gov (Registry). United States National Library of Medicine. 2020-04-30. NCT04368728. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-07-14.
↑  
"A Multi-site Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults". EU Clinical Trials Register (Registry). European Union. 2020-04-14. EudraCT 2020-001038-36. เก็บจากแหล่งเดิมเมื่อ 2020-04-22. สืบค้นเมื่อ 2020-04-22.
↑  Farge, E; Revill, J (2021-01-05). "WHO recommends two doses of Pfizer COVID-19 vaccine within 21-28 days". Reuters. Geneva. สืบค้นเมื่อ 2021-03-05.
↑  
Keaten, J (2021-01-08). "WHO: Amid short supplies, vaccine doses can be 6 weeks apart". Associated Press. Geneva. สืบค้นเมื่อ 2021-03-06.
↑  
"COVID vaccine: Moderna shots can be 6 weeks apart, WHO says". Deutsche Welle. 2021-01-26. สืบค้นเมื่อ 2021-03-06.
↑  
"Coronavirus (COVID-19) Update: FDA Allows More Flexible Storage, Transportation Conditions for Pfizer-BioNTech COVID-19 Vaccine" (Press release). Food and Drug Administration (FDA). 2021-02-25. สืบค้นเมื่อ 2021-03-05.
↑  
"Pfizer-BioNTech COVID-19 Vaccine EUA Fact Sheet for Healthcare Providers" (PDF). Pfizer. 2021-02-25. สืบค้นเมื่อ 2021-02-25.
↑  "Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine". Pfizer. สืบค้นเมื่อ 2020-12-11 – โดยทาง Business Wire.
↑  Lovelace Jr., Berkeley (2020-11-18). "Pfizer says final data analysis shows Covid vaccine is 95% effective, plans to submit to FDA in days". CNBC (ภาษาอังกฤษ).
↑  
Polack, FP; Thomas, SJ; Kitchin, N; Absalon, J; Gurtman, A; Lockhart, S;  และคณะ (December 2020). "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine". The New England Journal of Medicine. 383 (27): 2603–15. doi:10.1056/NEJMoa2034577. PMC 7745181. PMID 33301246.
↑  
"FDA Review of Efficacy and Safety of Pfizer-BioNTech COVID-19 Vaccine Emergency Use Authorization Request". U.S. Food and Drug Administration (FDA). 2020-12-10. สืบค้นเมื่อ 2020-12-11.  บทความนี้รวมเอาเนื้อความจากแหล่งอ้างอิงนี้ ซึ่งเป็นสาธารณสมบัติ
↑  Erman, Michael (2020-11-18). "Pfizer ends COVID-19 trial with 95% efficacy, to seek emergency-use authorization". Reuters. สืบค้นเมื่อ 2020-11-18.
1 2 3  Zimmer, Carl (2020-11-20). "2 Companies Say Their Vaccines Are 95% Effective. What Does That Mean? You might assume that 95 out of every 100 people vaccinated will be protected from Covid-19. But that's not how the math works". The New York Times. สืบค้นเมื่อ 2020-11-21.
↑  
"A Study of Ad26.COV2.S in Adults". ClinicalTrials.gov, US National Library of Medicine. 2020-08-04. เก็บจากแหล่งเดิมเมื่อ 2020-09-16. สืบค้นเมื่อ 2020-08-23.
↑  
"A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants". ClinicalTrials.gov. US National Library of Medicine. เก็บจากแหล่งเดิมเมื่อ 2020-09-26.
↑  Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19 (Briefing). U.S. Food and Drug Administration (FDA). 2021-02-26. p. 6. สืบค้นเมื่อ 2021-03-06. The vaccine, known as Ad26.COV2.S, is a replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding a stabilized variant of the SARS-CoV-2 S protein.
1 2  Ledford, H (January 2021). "J&J's one-shot COVID vaccine offers hope for faster protection". Nature. doi:10.1038/d41586-021-00119-7. PMID 33526898.
↑  "Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial" (Press release). Johnson & Johnson. 2021-01-29. สืบค้นเมื่อ 2021-01-29.
1 2 3 4  "Janssen COVID-19 Vaccine - ad26.cov2.s injection, suspension". DailyMed. U.S. National Institutes of Health. สืบค้นเมื่อ 2021-03-15.
1 2  Chen, Wei; Al Kaabi, Nawal (2020-07-18). "A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells)". Chinese Clinical Trial Registry. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-08-15.
↑  Xia, S; Zhang, Y; Wang, Y; Wang, H; Yang, Y; Gao, GF;  และคณะ (January 2021). "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial". The Lancet. Infectious Diseases. 21 (1): 39–51. doi:10.1016/S1473-3099(20)30831-8. PMC 7561304. PMID 33069281.
↑  Elbahrawy, F; Lyu, D; Omar, A; Che, C; Paton, J (2020-12-09). "China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says". Bloomberg News. สืบค้นเมื่อ 2020-03-05. CNBG's vaccine can be transported and stored at normal refrigerated temperatures.
1 2 3  Al Kaabi, N; Zhang, Y; Xia, S; Yang, Y; Al Qahtani, MM; Abdulrazzaq, N;  และคณะ (May 2021). "Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial". JAMA. doi:10.1001/jama.2021.8565. PMC 8156175. PMID 34037666.
↑  Yang, Yunkai. "A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above". ClinicalTrials.gov. เก็บจากแหล่งเดิมเมื่อ 2020-09-14. สืบค้นเมื่อ 2020-09-15.
↑  "Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)". ClinicalTrials.gov. สืบค้นเมื่อ 2020-09-28.
↑  "A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells)". chictr.org.cn. Chinese Clinical Trial Register (ChiCTR). คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2020-12-31. สืบค้นเมื่อ 2020-12-15.
↑  "Bahrain allows Sinopharm COVID-19 vaccine candidate use in frontline workers". MSN. Reuters. สืบค้นเมื่อ 2020-11-03.
↑  
"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19". ClinicalTrials.gov (Registry). United States National Library of Medicine. 2020-07-14. NCT04470427. สืบค้นเมื่อ 2020-07-27.
↑  
Palca, Joe (2020-07-27). "COVID-19 vaccine candidate heads to widespread testing in U.S." NPR. เก็บจากแหล่งเดิมเมื่อ 2020-08-03. สืบค้นเมื่อ 2020-07-27.
↑  "Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)". ClinicalTrials.gov. 2020-03-16. NCT04283461. สืบค้นเมื่อ 2021-03-05.
↑  "WHO experts issue recommendations on Moderna COVID-19 vaccine". Reuters. Geneva. 2021-01-26. สืบค้นเมื่อ 2021-03-05.
↑  "Fact Sheet for Healthcare Providers Administering Vaccine" (PDF) (Fact sheet). U.S. Food and Drug Administration (FDA). December 2020. สืบค้นเมื่อ 2021-03-05.
↑  "Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine". National Institutes of Health (NIH). 2020-11-15.
↑  Baden, L; Essink, B; Kotloff, K; Frey, S; Novak, R; Diemert, D;  และคณะ (December 2020). "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine". New England Journal of Medicine. doi:10.1056/NEJMoa2035389. PMID 33378609.
↑  "An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" Vaccine Against COVID-19". ClinicalTrials.gov. 2020-06-17. NCT04436471. สืบค้นเมื่อ 2021-03-05.
↑  Jones, I; Roy, P (February 2021). "Sputnik V COVID-19 vaccine candidate appears safe and effective". Lancet. 397 (10275): 642–43. doi:10.1016/S0140-6736(21)00191-4. PMC 7906719. PMID 33545098.
↑  Sagdiev, R; Ivanova, P (2020-11-16). "Russia focuses on freeze-dried vaccine doses as transport fix". Reuters. Moscow. สืบค้นเมื่อ 2021-03-05.
↑  "Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19". clinicaltrials.gov. เก็บจากแหล่งเดิมเมื่อ 2020-09-12. สืบค้นเมื่อ 2020-09-11.
1 2  Logunov, DY; Dolzhikova, IV; Shcheblyakov, DV; Tukhvatulin, AI; Zubkova, OV; Dzharullaeva, AS;  และคณะ (February 2021). "Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia". Lancet. 397 (10275): 671–81. doi:10.1016/S0140-6736(21)00234-8. PMC 7852454. PMID 33545094.
↑  "Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus". ClinicalTrials.gov. Health Ministry of the Russian Federation. 2020-09-25. สืบค้นเมื่อ 2021-01-18.
↑  
Kumar, Shivani (2020-12-01). "Sputnik-V from Russia arrives in India for clinal trials". Hindustan Times.
↑  
"Clinical trial: 17 volunteers given Russia's Sputnik V Covid-19 vaccine in Pune". The Indian Express. 2020-12-06.
↑  
"Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Venezuela". ClinicalTrials.gov. Health Ministry of the Russian Federation. 2020-11-24. สืบค้นเมื่อ 2021-01-18.
↑  
"Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Venezuela". ClinicalTrials.gov. Health Ministry of the Russian Federation. 2020-11-24. สืบค้นเมื่อ 2021-01-18.
↑  "UAE begins trials of Russia's Sputnik V Covid-19 vaccine". ClinicalTrials. 2021-01-08.
1 2  
"Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection (COVID-19) (Renqiu)". ClinicalTrials.gov (Registry). United States National Library of Medicine. 2020-05-12. NCT04383574. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-07-14.
↑  
"Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV)". ClinicalTrials.gov (Registry). United States National Library of Medicine. 2020-07-02. NCT04456595. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-08-03.
↑  PT. Bio Farma (2020-08-10). "A Phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-COV-2 inactivated vaccine in healthy adults aged 18-59 years in Indonesia". Registri Penyakit Indonesia. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-08-15.
↑  "The Sinovac COVID-19 vaccine: What you need to know". World Health Organization. 2021-06-02. สืบค้นเมื่อ 2021-07-03.
↑  Tan, Yvette (2021-01-14). "Covid: What do we know about China's coronavirus vaccines?". BBC News Online. สืบค้นเมื่อ 2020-03-05.
↑  Tanriover, Mine Durusu; Doğanay, Hamdi Levent; Akova, Murat; Güner, Hatice Rahmet; Azap, Alpay; Akhan, Sıla;  และคณะ (2021-07-08). "Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey". The Lancet (ภาษาอังกฤษ). doi:10.1016/S0140-6736(21)01429-X. ISSN 0140-6736. S2CID 235770533.
↑  
"Reporte COVID-19: Vacuna Coronavac Tiene Un 90,3% De Efectividad Para Prevenir El Ingreso a UCI" [COVID-19 report: CoronaVac vaccine is 90.3% effective in preventing admission to the ICU]. Ministerio de Salud - Gobierno de Chile (ภาษาสเปน). 2021-05-17.
↑  
"Coronavirus en Chile: Reporte Minsal 17 de Mayo" [Coronavirus in Chile: Minsal report May 17]. YouTube (ภาษาสเปน). 2021-05-17.
↑  Costa, AG (2021-04-11). "Estudo clínico que comprova maior eficácia da Coronavac é enviado para Lancet" [Clinical study proving greater efficacy of Coronavac is submitted to The Lancet]. CNN Brasil (ภาษาโปรตุเกส). São Paulo. สืบค้นเมื่อ 2021-04-12.
↑  "Tests show coronavirus vaccine by China's Sinovac is safe, says Brazil's Butantan Institute". เก็บจากแหล่งเดิมเมื่อ 2020-10-29. สืบค้นเมื่อ 2020-10-29.
↑  "Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults". ClinicalTrials.gov. 2020-11-05. NCT04617483. สืบค้นเมื่อ 2021-06-06.
↑  "Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults (CoronaVac3CL)". ClinicalTrials.gov. 2020-12-03. NCT04651790. สืบค้นเมื่อ 2021-06-06.
↑  "Chile initiates clinical study for COVID-19 vaccine". เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-10-29.
↑  "A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II/III Clinical Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Inactivated (Vero Cell) Vaccine in the Elderly 60-80 Years of Age, Coronovac ENCOV19 Study". registry.healthresearch.ph. Philippine Health Research Registry. สืบค้นเมื่อ 2021-04-23.
↑  "Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated". ClinicalTrials.gov. 2020-10-08. เก็บจากแหล่งเดิมเมื่อ 2020-10-20. สืบค้นเมื่อ 2020-10-22.
↑  
"An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine (Projeto S)". ClinicalTrials.gov. 2021-02-10. NCT04747821. สืบค้นเมื่อ 2021-06-01.
↑  
"Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Public Safety Workers With Risk Factors for Severity (COVACMANAUS)". ClinicalTrials.gov. 2021-03-09. NCT04789356. สืบค้นเมื่อ 2021-06-01.
↑  "Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers (BBV152)". ClinicalTrials.gov. 2020-07-15. NCT04471519.
1 2  "Covovax, Biological E: What we know about India's new Covid-19 vaccines". BBC News Online. 2021-06-16. สืบค้นเมื่อ 2021-06-19. The two doses are given four weeks apart. The vaccine can be stored at 2C to 8C.
↑  "An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers - Full Text View - ClinicalTrials.gov". clinicaltrials.gov (ภาษาอังกฤษ). สืบค้นเมื่อ 2020-11-26.
↑  Koshy, Jacob (2021-04-21). "Updated data from Covaxin phase 3 trial shows 78% efficacy". The Hindu. ISSN 0971-751X. สืบค้นเมื่อ 2021-04-24.
↑  Jha, Sujeet (2021-06-24). "A prospective, longitudinal, observational, post licensure vaccine evaluation study to assess the effectiveness of COVID-19 vaccine among the Healthcare workers of Max group of hospitals". ctri.nic.in. Clinical Trials Registry India. CTRI/2021/01/030782. สืบค้นเมื่อ 2021-07-03.
↑  "Russia Approves Single-Dose Sputnik Light Covid Vaccine For Use". NDTV Coronavirus. 2021-05-06.
1 2 3  "Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light (SPUTNIK-LIGHT)".
↑  "Single dose vaccine, Sputnik Light, authorized for use in Russia" (Press release). Russian Direct Investment Fund. 2021-05-06. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-07-02. สืบค้นเมื่อ 2021-05-07.
↑  Leo, Leory (2021-05-07). "Russia OKs single-dose Sputnik Light vaccine". Mint.
1 2  "Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19". ClinicalTrials.gov (Registry). United States National Library of Medicine. 2020-11-13. NCT04540419. สืบค้นเมื่อ 2020-11-17.
↑  Zhu, FC; Guan, XH; Li, YH; Huang, JY; Jiang, T; Hou, LH;  และคณะ (August 2020). "Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial". Lancet. 396 (10249): 479–88. doi:10.1016/s0140-6736(20)31605-6. PMC 7836858. PMID 32702299.
1 2 3 4  Peshimam, G; Farooq, U (2021-02-08). "CanSinoBIO's COVID-19 vaccine 65.7% effective in global trials, Pakistan official says". Reuters. Islamabad. สืบค้นเมื่อ 2021-03-05. its single-dose regimen and normal refrigerator storage requirement could make it a favourable option for many countries
↑  
Lazcano, Patricio (2020-11-15). "Así funcionan las cuatro vacunas que se probarán en Chile". La Tercera. สืบค้นเมื่อ 2020-12-15.
↑  Martinez, Ana Isabel (2020-11-03). "CanSino Biologics delivers COVID-19 vaccine to Mexico for late-stage trial". Reuters. สืบค้นเมื่อ 2020-11-04.
↑  Ng, Eric (2020-10-28). "China's CanSino trials Covid-19 vaccine in 'high disease burden' nations". South China Morning Post. สืบค้นเมื่อ 2020-11-04.
↑  Nafisa, Eltahir (2020-08-09). "CanSino to start Phase III trial of COVID-19 vaccine in Saudi". Reuters. สืบค้นเมื่อ 2020-11-04.
↑  Gou, Jinbo. "Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above". ClinicalTrials.gov. เก็บจากแหล่งเดิมเมื่อ 2020-09-18. สืบค้นเมื่อ 2020-09-17.
1 2  
China National Biotec Group Company Limited (2020-10-29). G42 Healthcare company, Abu Dhabi Health Services Company, Wuhan Institute of Biological Products Co., Ltd, Beijing Institute of Biological Products Co Ltd. "Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above". ClinicalTrials.gov.
1 2  Universidad Peruana Cayetano Heredia (2020-11-03). National University of San Marcos, Peru. "Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru (Covid-Peru)". ClinicalTrials.gov.
↑  "Two Chinese-developed COVID-19 vaccines under review". National Medical Products Administration. 2021-02-25. สืบค้นเมื่อ 2021-04-11.
↑  Xia, S; Duan, K; Zhang, Y; Zhao, D; Zhang, H; Xie, Z;  และคณะ (September 2020). "Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials". JAMA. 324 (10): 951–960. doi:10.1001/jama.2020.15543. PMC 7426884. PMID 32789505.
↑  "Chinese Clinical Trial Register (ChiCTR) - The world health organization international clinical trials registered organization registered platform". www.chictr.org.cn. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2020-12-31. สืบค้นเมื่อ 2021-04-01.
1 2 3  
Ryzhikov, AB; Ryzhikov, EA; Bogryantseva, MP; Usova, SV; Danilenko, ED; Nechaeva, EA;  และคณะ (2021). "A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the "EpiVacCorona" Vaccine for the prevention of COVID-19, in volunteers aged 18-60 years (Phase I-II)". Russian Journal of Infection and Immunity. 11 (2): 283–96. doi:10.15789/2220-7619-ASB-1699.
↑  
Ryzhikov, AB; Ryzhikov, EA; Bogryantseva, MP; Usova, SV; Danilenko, ED; Imatdinov, IR;  และคณะ (2021). "Immunogenicity and Protectivityof the Peptide Vaccine againstSARS-CoV-2". Annals of the Russian Academy of Medical Sciences. 76 (1): 5–19. doi:10.15690/vramn1528.
↑  Benedyczak, J (2021-02-12). Russia's Problems in the Vaccine Race (Bulletin). Polish Institute of International Affairs. สืบค้นเมื่อ 2021-03-06. the Sputnik V and EpiVacCorona can be transported and stored at temperatures of +2 to + 8° C
↑  "О регистрации вакцины ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора "ЭпиВакКорона"" [On the registration of the vaccine FBSI SSC VB "Vector" Rospotrebnadzor "EpiVacCorona"]. rospotrebnadzor.ru (ภาษารัสเซีย). Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing. 2020-10-14. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2020-11-01. สืบค้นเมื่อ 2021-05-12. Запланированы два пострегистрационных клинических исследования: клиническое исследование с участием 150 человек старше 60 лет и многоцентровое клиническое исследование с участием 40 000 добровольцев. (translated) Two post-marketing clinical trials are planned: a clinical trial involving 150 people over 60 years of age and a multicenter clinical trial involving 40,000 volunteers.
↑  "Russian EpiVacCorona Vaccine Has No Adverse Effects". OREANDA-NEWS. 2021-01-13.
↑  Center of Virology and Biotechnology "Vector" (2021-03-02). "Multicenter Double-blind Placebo-controlled Comparative Randomized Study of the Tolerability, Safety, Immunogenicity and Prophylactic Efficacy of the EpiVacCorona Peptide Antigen-based Vaccine for the Prevention of COVID-19, With the Participation of 3000 Volunteers Aged 18 Years and Above (Phase III-IV)". สืบค้นเมื่อ 2021-05-12. {{cite journal}}: Cite journal ต้องการ |journal= (help)
↑  "Sputnik V's ugly cousin". Meduza. 2021-03-27. สืบค้นเมื่อ 2021-05-12.
↑  "Volunteers break rank to raise doubts in trial of Russia's second COVID-19 vaccine". Reuters. 2021-03-26. สืบค้นเมื่อ 2021-05-12.
1 2  "A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19". ClinicalTrials.gov.
↑  "China's CAS COVID-19 vaccine induces immune response in mid-stage tests". Reuters. Beijing. 2020-12-23. สืบค้นเมื่อ 2021-03-08.
↑  Yang, S; Li, Y; Dai, L; Wang, J; He, P; Li, C;  และคณะ (March 2021). "Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials". The Lancet. Infectious Diseases. doi:10.1016/S1473-3099(21)00127-4. PMC 7990482. PMID 33773111.
↑  
Pinghui, Z (2020-11-20). "Fifth Chinese Covid-19 vaccine candidate ready to enter phase 3 trials". South China Morning Post. สืบค้นเมื่อ 2020-12-26.
↑  
Ying, TP (2020-12-07). "MYEG to conduct phase 3 clinical trial for China's Covid-19 vaccine in Msia". New Straits Times. สืบค้นเมื่อ 2020-12-28.
1 2  "ABDALA Clinical Study - Phase III". rpcec.sld.cu. Registro Público Cubano de Ensayos Clínicos. สืบค้นเมื่อ 2021-03-22.
1 2  Faiola, Anthony; Herrero, Ana Vanessa (2021-03-29). "Against the odds, Cuba could become a coronavirus vaccine powerhouse". The Washington Post. สืบค้นเมื่อ 2021-07-02. Cuban officials say they’re developing cheap and easy-to-store serums. They are able to last at room temperature for weeks, and in long-term storage as high as 46.4 degrees
↑  "Cuba says its Abdala vaccine among the most effective in the world". Financial Express. 2021-06-24. สืบค้นเมื่อ 2021-07-02.
↑  "Briefing with Deputy Prime Minister Tatyana Golikova, Health Minister Mikhail Murashko and Head of Rospotrebnadzor Anna Popova". Government of Russia. 2021-01-18. สืบค้นเมื่อ 2021-02-20.
↑  Ryumin, A (2021-02-20). "Russia registers its third COVID-19 vaccine CoviVac". TASS. Moscow. สืบค้นเมื่อ 2021-03-06.
1 2  Ivanova, P (2021-02-08). "Russia approves its third COVID-19 vaccine, CoviVac". Reuters. Moscow. สืบค้นเมื่อ 2021-03-05. 'The CoviVac shot is given in two doses, 14 days apart. It is transported and stored at normal fridge temperatures, of 2 to 8 degrees Celsius (35.6 to 46.4 Fahrenheit),' Deputy Prime Minister Tatiana Golikova said in a government briefing in January.
↑  "Центр Чумакова обнародовал сроки третьей фазы испытаний вакцины против COVID-19" [Chumakov Center announced the timing of the third phase of trials of the vaccine against COVID-19]. govoritmoskva.ru (ภาษารัสเซีย). 2021-04-19. สืบค้นเมื่อ 2021-04-19.
↑  AFP (2021-02-20). "Russia registers third COVID-19 vaccine". The Times of Israel.
↑  Yergaliyeva, A (2020-12-20). "Kazakhstan Begins Vaccinating 3,000 Volunteers With Self-Made QazCovid-in". The Astana Times. สืบค้นเมื่อ 2021-03-02.
↑  Meyer, David (2021-04-26). "A new vaccine on the scene: Kazakhstan begins rollout of homegrown QazVac". Fortune. สืบค้นเมื่อ 2021-04-26.
↑  Gotev, Georgi (2021-04-23). "Kazakhstan launches QazVac, its own COVID-19 vaccine". EURACTIV.
1 2  "Immunogenicity, Efficacy and Safety of QazCovid-in COVID-19 Vaccine". ClinicalTrials.gov. 2020-12-31. NCT04691908.
1 2  "A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)". ClinicalTrials.gov. 2021-04-21. NCT04852705. สืบค้นเมื่อ 2021-04-22.
↑  "COVIran Barakat: Iran launches human trials of its COVID vaccine". aljazeera. 2019-12-29.
1 2  "A double-blind, randomized, placebo-controlled Phase II/III Clinical trial to evaluate the safety and efficacy of COVID-19 inactivated vaccine (Shifa-Pharmed) in a population aged 18 to 75 years". Iranian Registry of Clinical Trials. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-04-23. สืบค้นเมื่อ 2021-03-27.
↑  "COVIRAN vaccine closer to completing human trials". Theran Times. 2021-06-08.
↑  "Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19". ClinicalTrials.gov. 2020-06-02. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-07-14.
1 2  "The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19". ClinicalTrials.gov. NCT04659239. สืบค้นเมื่อ 2021-03-10.
1 2  
"SOBERANA 02-FaseIII". Registro Público Cubano de Ensayos Clínicos. RPCEC00000354.
↑  
Held, S (2021-03-04). "Cuba's Soberana 02 SARS-CoV-2 vaccine candidate moves to phase III trials". Bioworld. สืบค้นเมื่อ 2021-03-10.
↑  "Cuba Soberana 02 COVID-19 Vaccine". precisionvaccinations.com. 2021-06-08. สืบค้นเมื่อ 2021-04-22.
1 2  "A prospective, randomized, adaptive, phase I/II clinical study to evaluate the safety and immunogenicity of Novel Corona Virus -2019-nCov vaccine candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects". ctri.nic.in (Registry). Clinical Trials Registry India. 2020-12-15. CTRI/2020/07/026352. เก็บจากแหล่งเดิมเมื่อ 2020-11-22.
↑  "3-dose Zydus Cadila likely to seek emergency nod for ZyCoV-D in a week: Report". Hindustan Times. 2021-06-18. สืบค้นเมื่อ 2021-08-20.
↑  "Zydus receives EUA from DCGI for ZyCoV-D, the only needle-free COVID vaccine in the world". Cision PR Newswire. 2021-08-20.
↑  
"Zydus Cadila gets DCGI nod to initiate Phase-3 clinical trials for COVID-19 vaccine". The Hindu. 2021-01-03.
↑  
"Novel Corona Virus-2019-nCov vaccine by intradermal route in healthy subjects". ctri.nic.in. Clinical Trials Registry India. สืบค้นเมื่อ 2021-04-10.
↑  
Thacker, T. "Zydus Cadila to test ZyCoV-D on 30,000 patients in Phase-3 trials". The Economic Times. สืบค้นเมื่อ 2020-12-16.
↑  "DBT-BIRAC supported indigenously developed DNA Vaccine Candidate by Zydus Cadila, approved for Phase III clinical trials" (Press release). Press Information Bureau. 2021-01-03.
↑  "COVID-19 vaccine tracker (Choose vaccines tab, apply filters to view select data)". Milken Institute. 2020-12-08. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2020-03-27. สืบค้นเมื่อ 2020-12-11.
↑  
"Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant". ClinicalTrials.gov (Registry). United States National Library of Medicine. 2020-04-30. NCT04368988. เก็บจากแหล่งเดิมเมื่อ 2020-07-14. สืบค้นเมื่อ 2020-07-14.
↑  
"Hope to launch Covovax by September, says Serum Institute CEO". mint. 2021-03-27. สืบค้นเมื่อ 2021-03-28.